April 30, 2026, 11:00 AM ET
Increasingly, antibody drug development requires quick and holistic assessment from the discovery stage with a powerful platform, which demands experienced scientists make smart and strategic choices. We will discuss how Biointron‘s unique single B cell sorting-based antibody screening can help identify a population of diverse and functional hits with a shortened timeline. Integrated with our high-throughput expression, validation and developability assay platforms, the path from hits to candidate can be more faster and more efficient with data beyond binding alone.
Antibody discovery platforms in action
Faster, smarter early-stage decision-making
Rapid identification of diverse, functional hits via single B cell screening
Accelerated path from hits to candidates with integrated, data-rich workflows
Lei Shi, PhD, Senior Vice President at Biointron
Lei Shi, PhD. is Senior Vice President of Biointron. He has more than 20 years of experience in antibody discovery. Previously, Lei worked for a number of pharmaceutical and biotech companies such as Johnson & Johnson with increasing responsibilities. He completed his postdoc research at MGH and Harvard Medical School and has an Executive Master's degree from the University of Pennsylvania.
AI is transforming antibody discovery, but better models only come from better d……
The antibody therapeutics sector is rapidly evolving, transitioning from traditi……
Biointron’s 2026 Lunch & Learn, held at CIC Cambridge on May 8, 2026, featured e……
ScientistとScience Exchangeとのご利用可能です。
